A chimeric SM5-1 antibody inhibits hepatocellular carcinoma cell growth and induces caspase-dependent apoptosis

被引：8

作者：

Dai, Jianxin ^{[1
]}

Jin, Jun ^{[1
]}

Li, Bohua ^{[1
,2
]}

Wang, Hao ^{[1
,2
]}

Hou, Sheng ^{[1
,2
]}

Qian, Weizhu ^{[1
,2
]}

Kou, Geng ^{[1
,2
]}

Zhang, Dapeng ^{[1
]}

Li, Jing ^{[2
]}

Tan, Min

Ma, Jing ^{[1
,2
]}

Guo, Yajun ^{[1
,2
]}

机构：

[1] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China

[2] Shanghai Ctr Cell Engn & Antibody, Shanghai 201203, Peoples R China

来源：

CANCER LETTERS | 2007年 / 258卷 / 02期

基金：

中国国家自然科学基金;

关键词：

SM5-1; chimeric antibody; apoptosis; caspase-10; hepatocellular carcinoma;

D O I：

10.1016/j.canlet.2007.09.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

cSM5-1 is a mouse-human chimeric antibody which has a high specificity for hepatocellular carcinoma, melanoma and breast cancer. In this study, cSM5-1 was found to be able to inhibit cell growth and induce apoptosis in hepatocellular carcinoma cells. The antitumor activity of cSM5-1 was closely correlated with the expression level of the SM5-1 binding protein in the cancer cells. The role of caspases in cSM5-1-induced apoptosis was also investigated, indicating that cSM5-1-induced apoptosis was partially caspase-dependent and caspase-10 played a critical role. These in vitro data indicate that cSM5-1 has the potential to be a promising candidate for cancer treatment. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：208 / 214

页数：7

共 21 条

[1] HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].

CARTER, P ;

PRESTA, L ;

GORMAN, CM ;

RIDGWAY, JBB ;

HENNER, D ;

WONG, WLT ;

ROWLAND, AM ;

KOTTS, C ;

CARVER, ME ;

SHEPARD, HM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289

[2] Initiator caspases in apoptosis signaling pathways [J].

Chen, M ;

Wang, J .

APOPTOSIS, 2002, 7 (04) :313-319

[3] Caspases: the executioners of apoptosis [J].

Cohen, GM .

BIOCHEMICAL JOURNAL, 1997, 326 :1-16

[4]

Harada K, 2002, CANCER RES, V62, P5897

[5] Engineering antibodies for the clinic [J].

Holliger, P ;

Bohlen, H .

CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :411-419

[6] Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions [J].

Li, BH ;

Wang, H ;

Dai, JX ;

Ji, JJ ;

Qian, WZ ;

Zhang, DP ;

Hou, S ;

Guo, YJ .

IMMUNOLOGY, 2005, 116 (04) :487-498

[7] Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody [J].

Li, Bohua ;

Wang, Hao ;

Zhang, Dapeng ;

Qian, Wezhu ;

Hou, Sheng ;

Shi, Shu ;

Zhao, Lei ;

Kou, Geng ;

Cao, Zhiguo ;

Dai, Jianxin ;

Guo, Yajun .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 357 (04) :951-956

[8] Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10 [J].

Ng, PWP ;

Porter, AG ;

Jänicke, RU .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (15) :10301-10308

[9] THE GENETIC-ENGINEERING OF MONOCLONAL-ANTIBODIES [J].

OWENS, RJ ;

YOUNG, RJ .

JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 168 (02) :149-165

[10] Inactivating mutations of the caspase-10 gene in gastric cancer [J].

Park, WS ;

Lee, JH ;

Shin, MS ;

Park, JY ;

Kim, HS ;

Lee, JH ;

Kim, YS ;

Lee, SN ;

Xiao, WH ;

Park, CH ;

Lee, SH ;

Yoo, NJ ;

Lee, JY .

ONCOGENE, 2002, 21 (18) :2919-2925

← 1 2 3 →